澳大利亚维多利亚州产前产后联合队列中染色体异常及22q11缺失综合征的最低患病率估计
该研究基于澳大利亚维多利亚州24个月内8826例产前和产后染色体分析,发现整个队列主要染色体异常频率为28.2%,且随发育阶段显著下降:流产组50.9%、产前组21.3%、产后组15.6%。致病性拷贝数变异频率则随发育阶段显著上升,活产婴儿中为6.0%。22q11.2缺失综合征估计患病率为1/4558活产。
要点
- 主要染色体异常频率随发育阶段下降:流产50.9%、产前21.3%、产后15.6%。
- 致病性CNV频率随发育阶段上升:流产1.9%、产前2.2%、产后4.9%。
- 22q11.2缺失综合征估计患病率为1/4558活产。
核心结论
- 整个队列主要染色体异常频率为28.2%(2493/8826)。
- 22q11.2缺失综合征估计患病率为1/4558活产。
研究设计与样本
- 基于澳大利亚维多利亚州2015年1月至2016年12月24个月的人群队列研究。
- 纳入所有侵入性产前诊断样本及妊娠组织、≤12月龄婴儿的产后样本,共8826例染色体分析。
主要发现
- 主要染色体异常频率随发育阶段显著下降:流产组50.9%、产前组21.3%、产后组15.6%(χ2趋势=790.0,P<0.0001)。
- 活产婴儿亚组主要染色体异常频率为13.4%(244/1816)。
- 致病性CNV频率随发育阶段显著上升:流产组1.9%(50/2573)、产前组2.2%(82/3661)、产后组4.9%(127/2592)(χ2趋势=39.72,P<0.0001)。
- 活产婴儿亚组CMA检出致病性CNV频率为6.0%(109/1816)。
- 共诊断38例22q11.2缺失综合征,包括1例流产、15例产前和22例产后。
关键数值与推荐
- 91.2%的染色体分析采用染色体微阵列分析(CMA)。
- 22q11.2缺失综合征患病率估计为1/4558活产(排除流产病例并校正重复检测后)。
临床怎么用
- 在高收入地区,CMA已成为妊娠丢失、胎儿诊断和新生儿/婴儿评估的一线染色体检查。
- 整合产前和产后诊断数据有助于估计重要先天综合征的患病率。
局限性
- 11.6%的产后样本临床信息缺失,流产样本极少提供孕周。
- 因临床转诊数据不完整,无法获得终止妊娠和死产率,不能对妊娠或婴儿结局作出结论。
- 未收集儿童期和成人期诊断的22q11.2缺失综合征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the frequency of major chromosome abnormalities in a population-based diagnostic data set of genomic tests performed on miscarriage, fetal and infant samples in a state with >73 000 annual births? SUMMARY ANSWER: The overall frequency of major chromosome abnormalities in the entire cohort was 28.2% (2493/8826), with a significant decrease in the detection of major chromosome abnormalities with later developmental stage, from 50.9% to 21.3% to 15.6% of tests in the miscarriage, prenatal and postnatal cohorts, respectively. WHAT IS KNOWN ALREADY: Over the past decade, technological advances have revolutionized genomic testing at every stage of reproduction. Chromosomal microarrays (CMAs) are now the gold standard of chromosome assessment in prenatal diagnosis and pediatrics. STUDY DESIGN, SIZE, DURATION: A population-based cohort study including all chromosome analysis was performed in the Australian state of Victoria during a 24-month period from January 2015 to December 2016. All samples obtained via invasive prenatal diagnosis and postnatal samples from pregnancy tissue and infants ≤12 months of age were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: A research collaboration of screening and diagnostic units in the Australian state of Victoria was formed (the Perinatal Record Linkage collaboration), capturing all instances of prenatal and postnatal chromosome testing performed in the state. Victoria has over 73 000 births per annum and a median maternal age of 31.5 years. We analyzed our population-based diagnostic data set for (i) chromosome assessment of miscarriage, prenatal diagnosis and postnatal samples; (ii) testing indications and diagnostic yields for each of these cohorts; (iii) and the combined prenatal/infant prevalence of 22q11.2 deletion syndrome (DS) as a proportion of all births ≥20 weeks gestation. MAIN RESULTS AND THE ROLE OF CHANCE: During the 24-month study period, a total of 8826 chromosomal analyses were performed on prenatal and postnatal specimens in Victoria. The vast majority (91.2%) of all chromosome analyses were performed with CMA.The overall frequency of major chromosome abnormalities in the entire cohort was 28.2% (2493/8826). There was a significant decreasing trend in the percentage of chromosome abnormalities with later developmental stage from 50.9% to 21.3% to 15.6% in the miscarriage, prenatal and postnatal cohorts, respectively (χ2 trend = 790.0, P < 0.0001). The total frequency of abnormalities in the live infant subgroup was 13.4% (244/1816). The frequencies of pathogenic copy number variants (CNVs) detected via CMA for the miscarriage, prenatal and postnatal cohorts were 1.9% (50/2573), 2.2% (82/3661) and 4.9% (127/2592), respectively. There was a significant increasing trend in the frequency of pathogenic CNVs with later developmental stage (χ2 trend = 39.72, P < 0.0001). For the subgroup of live infants, the pathogenic CNV frequency on CMA analysis was 6.0% (109/1816). There were 38 diagnoses of 22q11.2 DS, including 1 miscarriage, 15 prenatal and 22 postnatal cases. After excluding the miscarriage case and accounting for duplicate testing, the estimated prevalence of 22q11 DS was 1 in 4558 Victorian births. LIMITATIONS, REASONS FOR CAUTION: Clinical information was missing on 11.6% of postnatal samples, and gestational age was rarely provided on the miscarriage specimens. We were unable to obtain rates of termination of pregnancy and stillbirth in our cohort due to incomplete data provided by clinical referrers. We therefore cannot make conclusions on pregnancy or infant outcome following diagnostic testing. Childhood and adult diagnoses of 22q11 DS were not collected. WIDER IMPLICATIONS OF THE FINDINGS: Our study marks a complete transition in genomic testing from the G-banded karyotype era, with CMA now established as the first line investigation for pregnancy losses, fetal diagnosis and newborn/infant assessment in a high-income setting. Integration of prenatal and postnatal diagnostic data sets provides important opportunities for estimating the prevalence of clinically important congenital syndromes, such as 22q11 DS. STUDY FUNDING/COMPETING INTEREST(S): L.H. is funded by a National Health and Medical Research Council Early Career Fellowship (1105603); A.L. was funded by a Mercy Perinatal Research Fellowship; J.H. was funded by a National Health and Medical Research Council Senior Research Fellowship (10121252). The funding bodies had no role in the conduct of the research or the manuscript. Discretionary funding from the Murdoch Children's Research Institute has supported the prenatal diagnosis data collection and reporting over the years.Dr Ricardo Palma-Dias reports a commercial relationship with Roche Diagnostics, personal fees from Philips Ultrasound, outside the submitted work. Debbie Nisbet reports a commercial relationship with Roche Diagnostics, outside the submitted work. TRIAL REGISTRATION NUMBER: NA.
引用
- Hui L, Poulton A, Kluckow E, et al. A minimum estimate of the prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort. Hum Reprod. 2020. PMID: 32207823. doi:10.1093/humrep/dez286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。